Arrhythmias in cardiac amyloidosis: recognition and palliation
Cardiac amyloidosis changes the structure and electrical behavior of the heart at the same time. Amyloid deposits can thicken the ventricular walls, impair relaxation, disrupt the conduction system, and create atrial or ventricular arrhythmogenic substrates. Symptoms may therefore reflect heart failure, rhythm disturbance, autonomic dysfunction, or several of these processes together.
The two principal forms are immunoglobulin light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. Their treatments, tempo, and prognoses differ, yet both can produce bradyarrhythmias, atrial fibrillation, atrial standstill, atrioventricular block, and ventricular tachyarrhythmias. Recognizing the rhythm phenotype early helps clinicians select proportionate investigations and avoid therapies that worsen hypotension or congestion.
Specialist electrophysiology resources, including the Journal of Arrhythmia, can support clinicians who are integrating imaging, device data, and symptom-focused care. Management should address reversible risks and prevent distress, while remaining aligned with the person’s goals and the likely benefit of invasive treatment.
Why amyloid infiltration creates electrical instability
Amyloid infiltration increases ventricular wall thickness without producing the normal myocardial architecture associated with athletic hypertrophy or hypertensive remodeling. The deposits impair conduction through the atria, atrioventricular node, His-Purkinje system, and ventricular myocardium. Fibrosis and small-vessel disease may add ischemia or scar, further slowing impulse propagation and increasing re-entry potential.
Atrial arrhythmias are common because atrial infiltration and elevated filling pressures promote atrial dilation and electrical remodeling. Atrial fibrillation and flutter may cause a marked decline in cardiac output when ventricular filling is already restricted. Loss of coordinated atrial contraction can be particularly poorly tolerated in restrictive physiology, even when the ventricular rate appears controlled.
Bradycardia deserves equal attention. Sinus node dysfunction, chronotropic incompetence, and advanced atrioventricular block may present as fatigue, exertional intolerance, presyncope, or unexplained falls rather than classic palpitations. In advanced disease, autonomic neuropathy and low stroke volume can make a modest rhythm change clinically significant.
Recognizing the rhythm phenotype
A new arrhythmia in an older adult with unexplained increased ventricular wall thickness should prompt consideration of cardiac amyloidosis, especially when low-voltage QRS complexes, disproportionate wall thickening, bilateral carpal tunnel syndrome, neuropathy, orthostatic hypotension, or a history of biceps tendon rupture are present. The combination of low voltage and thickened walls is suggestive but not universal, so a normal ECG voltage does not exclude disease.
Symptoms can be nonspecific. Breathlessness, edema, dizziness, exercise intolerance, chest discomfort, and episodic weakness may arise from rapid atrial fibrillation, pauses, ventricular tachycardia, low cardiac output, or orthostatic hypotension. A careful symptom-rhythm correlation is more useful than assigning every complaint to heart failure.
The assessment should also review thyroid function, anemia, electrolytes, renal function, medication exposure, and sleep-disordered breathing. Thyroid disease can contribute to atrial fibrillation and may complicate interpretation of new rhythm symptoms; a focused review of thyroid and AF mechanisms is relevant when these conditions overlap. Medication-related bradycardia is common when beta-blockers, amiodarone, digoxin, or other rate-slowing agents are combined.
A practical diagnostic pathway
Begin with a 12-lead ECG, orthostatic vital signs, laboratory testing, and transthoracic echocardiography. Look for conduction delay, atrial arrhythmia, low voltage, pseudoinfarction patterns, increased wall thickness, biatrial enlargement, restrictive filling, reduced longitudinal strain, and right ventricular involvement. Ambulatory monitoring is valuable when symptoms are intermittent or when pauses and nonsustained ventricular tachycardia are suspected.
The underlying amyloid type must be established because AL amyloidosis requires urgent hematologic evaluation, while ATTR assessment generally includes bone scintigraphy after excluding a monoclonal protein and, when appropriate, genetic testing. Cardiac magnetic resonance, nuclear imaging, and tissue biopsy are selected according to the clinical context. Rhythm treatment should not delay evaluation for a rapidly progressive plasma-cell disorder.
| Rhythm problem | Findings that raise concern | Potentially useful assessment | Common management focus |
|---|---|---|---|
| Atrial fibrillation or flutter | Worsening congestion, hypotension, loss of exercise capacity | ECG, ambulatory monitoring, echocardiography | Anticoagulation assessment, cautious rate or rhythm control |
| Sinus node dysfunction | Fatigue, pauses, chronotropic incompetence, syncope | Extended monitoring, exercise assessment when safe | Medication review and pacing when symptoms are attributable |
| Atrioventricular block | Presyncope, syncope, broad QRS, progressive conduction delay | Serial ECGs, telemetry, ambulatory monitoring | Pacemaker evaluation, especially with advanced block |
| Ventricular tachycardia | Palpitations, syncope, scar, rapid clinical decline | Monitoring, imaging, electrolyte review | Reversible causes, individualized antiarrhythmic or device decisions |
| Refractory symptomatic bradycardia | Low output, dizziness, treatment-limiting pauses | Device consultation and goals-of-care review | Pacing weighed against procedural burden and prognosis |
Continuous inpatient telemetry is appropriate for acute decompensation, syncope with suspected conduction disease, or initiation of selected antiarrhythmic therapies. In outpatient care, patch monitors, implantable loop recorders, and device interrogations can reveal clinically important episodes that a single ECG misses.
Selecting rhythm treatment carefully
Rate control in cardiac amyloidosis is often difficult. Beta-blockers and nondihydropyridine calcium-channel blockers may reduce contractility or worsen hypotension in restrictive cardiomyopathy. Digoxin has historically raised concern because it may bind to amyloid fibrils and cause toxicity, although it can sometimes be used cautiously with low doses and close monitoring. Renal function, electrolytes, blood pressure, and drug interactions are central to any decision.
Amiodarone is frequently considered for atrial arrhythmias when ventricular function or blood pressure limits alternatives. Its long-term thyroid, pulmonary, hepatic, ocular, and neurologic toxicities are important, particularly in people with limited life expectancy or multisystem amyloidosis. Cardioversion may restore hemodynamics in selected patients, but recurrence is common and anticoagulation planning remains essential.
Anticoagulation for atrial fibrillation generally deserves a low threshold because intracardiac thrombus can occur even when conventional risk scores appear modest. Atrial mechanical dysfunction and blood stasis may persist during sinus rhythm or after cardioversion. Decisions should include bleeding risk, renal function, frailty, falls, gastrointestinal involvement, and the person’s priorities rather than relying on a score alone.
Devices, ventricular arrhythmias, and prognosis
Permanent pacing can relieve symptomatic sinus node dysfunction or atrioventricular block and may permit necessary treatment of tachyarrhythmias. The choice of pacing strategy depends on ventricular function, expected pacing burden, QRS characteristics, venous access, and procedural goals. Conduction-system pacing or cardiac resynchronization may be considered in selected patients, although evidence specific to amyloidosis remains less extensive than in other cardiomyopathies.
The benefit of an implantable cardioverter-defibrillator (ICD) is less predictable. A patient who survives a hemodynamically significant ventricular arrhythmia may have a clearer secondary-prevention indication. Primary prevention is more complex because sudden death may result from electromechanical dissociation or progressive pump failure, mechanisms an ICD cannot correct. Competing mortality, frailty, infection risk, and anticipated quality of life should be discussed explicitly.
Repeated shocks can become a major source of distress, particularly as systemic disease advances. Device programming, remote monitoring, and early specialist review can reduce avoidable shocks. When the goals of care change, ICD shock therapies may be deactivated while pacing is continued if it remains helpful; this is a treatment adjustment, not abandonment of care.
Palliative priorities in progressive disease
Palliative management can begin alongside disease-directed therapy. Its purpose is to reduce symptoms, clarify choices, and support family members while clinicians continue appropriate treatment for AL or ATTR amyloidosis. It is especially valuable when recurrent admissions, treatment toxicity, frailty, or progressive heart failure make the balance of benefit and burden uncertain.
Dyspnea may respond to carefully titrated diuretics, oxygen for documented hypoxemia, positioning, and low-dose opioids when breathlessness remains severe. Edema management must account for renal function and preload dependence. Orthostatic symptoms may require medication reduction, compression strategies when tolerated, hydration review, and practical measures such as slow position changes. Anxiety, insomnia, neuropathic pain, and gastrointestinal symptoms should be addressed as part of the same plan.
Communication should cover likely rhythm scenarios before a crisis occurs: recurrent atrial fibrillation, syncope, pacemaker dependence, ventricular tachycardia, emergency hospitalization, and ICD shocks. Patients may value longevity, alertness, remaining at home, avoiding procedures, or preserving independence differently. Resources and special issue collections can help clinicians and trainees keep pace with evolving evidence while developing individualized care plans.
A proportionate care framework
A practical plan combines rhythm surveillance with regular reassessment of function and treatment burden. At each review, clinicians can ask whether the arrhythmia is causing symptoms, whether an intervention is likely to improve meaningful daily activity, and whether the proposed treatment fits the person’s prognosis and preferences.
Useful recommendations include:
- Obtain an ECG and assess for conduction disease whenever new dizziness, syncope, fatigue, or unexplained functional decline occurs.
- Confirm the amyloid subtype and involve cardiology, electrophysiology, hematology, neurology, and palliative care according to the patient’s needs.
- Review rate-slowing drugs, anticoagulants, renal function, electrolytes, and orthostatic blood pressure at every significant clinical change.
- Discuss pacemaker, ICD, cardioversion, and device deactivation decisions before urgent deterioration limits shared decision-making.
- Record a clear plan for emergency care, symptom relief, preferred place of care, and family communication.
Follow-up should be flexible. A patient with early ATTR cardiomyopathy and manageable atrial fibrillation may benefit from longitudinal rhythm monitoring and active prevention of stroke. Someone with advanced AL disease, recurrent hypotension, and repeated hospitalizations may reasonably prioritize comfort, home-based support, and avoidance of invasive procedures. Both approaches can represent high-quality care when they are clinically informed and personally chosen.
Clinicians can use the Journal of Arrhythmia’s educational and research resources to refine recognition, treatment selection, and communication around cardiac amyloidosis. Early referral to electrophysiology and palliative care creates time for careful decisions, helping rhythm management remain aligned with comfort, safety, and the patient’s definition of benefit.